Allogene Therapeutics, Inc. $ALLO Shares Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP lifted its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 235.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 613,998 shares of the company’s stock after buying an additional 431,119 shares during the quarter. GSA Capital Partners LLP’s holdings in Allogene Therapeutics were worth $841,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Savant Capital LLC acquired a new position in Allogene Therapeutics during the third quarter worth $27,000. Russell Investments Group Ltd. grew its holdings in Allogene Therapeutics by 11,159.8% during the third quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company’s stock worth $27,000 after acquiring an additional 21,650 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in Allogene Therapeutics during the third quarter worth $30,000. Caitong International Asset Management Co. Ltd grew its holdings in Allogene Therapeutics by 5,267.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company’s stock worth $30,000 after acquiring an additional 23,599 shares during the period. Finally, Scientech Research LLC acquired a new position in Allogene Therapeutics during the third quarter worth $33,000. Institutional investors and hedge funds own 83.63% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on ALLO. Citigroup reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a report on Tuesday, April 14th. Jefferies Financial Group upped their price objective on Allogene Therapeutics from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Robert W. Baird boosted their price target on Allogene Therapeutics from $7.00 to $9.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th. JPMorgan Chase & Co. raised Allogene Therapeutics from an “underweight” rating to a “neutral” rating in a research note on Thursday, April 16th. Finally, Sanford C. Bernstein boosted their price target on Allogene Therapeutics from $1.60 to $3.85 and gave the stock a “market perform” rating in a research note on Tuesday, April 14th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.52.

Insider Buying and Selling at Allogene Therapeutics

In other news, CEO David D. Chang sold 47,763 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $2.47, for a total value of $117,974.61. Following the completion of the transaction, the chief executive officer directly owned 5,150,599 shares of the company’s stock, valued at $12,721,979.53. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 72,183 shares of company stock valued at $177,771 over the last ninety days. Insiders own 13.20% of the company’s stock.

Allogene Therapeutics Stock Up 2.0%

NASDAQ ALLO opened at $2.00 on Friday. Allogene Therapeutics, Inc. has a fifty-two week low of $0.98 and a fifty-two week high of $4.46. The stock has a market cap of $690.30 million, a price-to-earnings ratio of -2.60 and a beta of 0.46. The business has a fifty day moving average of $2.32 and a 200-day moving average of $1.88.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. As a group, analysts anticipate that Allogene Therapeutics, Inc. will post -0.72 EPS for the current year.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.